Spero Therapeutics Inc
NASDAQ:SPRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Banka BioLoo Ltd
NSE:BANKA
|
IN |
|
I
|
Integrated Design & Engineering Holdings Co Ltd
TSE:9161
|
JP |
|
Xiabuxiabu Catering Management (China) Holdings Co Ltd
HKEX:520
|
CN |
|
S
|
Shanghai Jin Jiang International Hotels Co Ltd
SSE:600754
|
CN |
|
C
|
Cooper Companies Inc
LSE:0I3I
|
US |
|
Hunya Foods Co Ltd
TWSE:1236
|
TW |
|
Tillys Inc
NYSE:TLYS
|
US |
|
A
|
Alior Bank SA
WSE:ALR
|
PL |
|
Megastar Foods Ltd
NSE:MEGASTAR
|
IN |
Spero Therapeutics Inc
Total Receivables
Spero Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
Total Receivables
$25.4m
|
CAGR 3-Years
185%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Spero Therapeutics Inc
Glance View
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
See Also
What is Spero Therapeutics Inc's Total Receivables?
Total Receivables
25.4m
USD
Based on the financial report for Dec 31, 2025, Spero Therapeutics Inc's Total Receivables amounts to 25.4m USD.
What is Spero Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
33%
Over the last year, the Total Receivables growth was -52%. The average annual Total Receivables growth rates for Spero Therapeutics Inc have been 185% over the past three years , 33% over the past five years .
